A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Summary

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).

Timeline

Start

2026-05-22

Primary completion

2028-06-12

Completion

2030-07-12

Drugs

Indications